Lyra Therapeutics (LYRA) Non Operating Income (2019 - 2025)

Quarterly Non Operating Income fell 61.15% to $169000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, down 28.39% year-over-year, with the annual reading at $2.1 million for FY2025, 28.39% down from the prior year.

Lyra Therapeutics' Non Operating Income history spans 7 years, with the latest figure at $169000.0 for Q4 2025.

  • Non Operating Income came in at $169000.0 for Q4 2025, down from $256000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.4 million in Q2 2025 to a low of $14000.0 in Q1 2022.
  • The 5-year median for Non Operating Income is $366500.0 (2024), against an average of $535400.0.
  • Year-over-year, Non Operating Income surged 7557.14% in 2023 and then plummeted 72.56% in 2025.
  • Lyra Therapeutics' Non Operating Income stood at $21000.0 in 2021, then surged by 4342.86% to $933000.0 in 2022, then skyrocketed by 43.41% to $1.3 million in 2023, then crashed by 67.49% to $435000.0 in 2024, then crashed by 61.15% to $169000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Non Operating Income are $169000.0 (Q4 2025), $256000.0 (Q3 2025), and $1.4 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 444,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 201.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -46.98 Mn
10 Lyra Therapeutics - - - 169,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 169,000.00
Sep 30, 2025 256,000.00
Jun 30, 2025 1.39 Mn
Mar 31, 2025 298,000.00
Dec 31, 2024 435,000.00
Sep 30, 2024 576,000.00
Jun 30, 2024 855,000.00
Mar 31, 2024 1.09 Mn
Dec 31, 2023 1.34 Mn
Sep 30, 2023 1.19 Mn
Jun 30, 2023 897,000.00
Mar 31, 2023 1.07 Mn
Dec 31, 2022 933,000.00
Sep 30, 2022 60,000.00
Jun 30, 2022 34,000.00
Mar 31, 2022 14,000.00
Dec 31, 2021 21,000.00
Sep 30, 2021 26,000.00
Jun 30, 2021 26,000.00
Mar 31, 2021 29,000.00
Dec 31, 2020 32,000.00
Sep 30, 2020 29,000.00
Jun 30, 2020 5,000.00
Mar 31, 2020 16,000.00
Dec 31, 2019 35,000.00
Sep 30, 2019 63,000.00
Jun 30, 2019 80,000.00
Mar 31, 2019 35,000.00